---
title: "Zai Lab Ltd. to Announce Fourth Quarter and Full Year Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275466803.md"
datetime: "2026-02-10T13:30:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275466803.md)
  - [en](https://longbridge.com/en/news/275466803.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275466803.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275466803.md) | [繁體中文](https://longbridge.com/zh-HK/news/275466803.md)


# Zai Lab Ltd. to Announce Fourth Quarter and Full Year Financial Results

Zai Lab Ltd. will announce its fourth quarter and full year 2025 financial results and provide recent corporate updates on February 26, 2026, before the opening of U.S. equity markets. Results will be released on the Company’s website at here. A conference call and webcast will be held on February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT). Participants can register for the webcast via the following link: Registration link for webcast (preferred) (here) or for the dial-in via Registration link for dial-in (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210221858) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Zai Lab Limited (ZLAB.US)](https://longbridge.com/en/quote/ZLAB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/en/news/278542482.md)
- [Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027](https://longbridge.com/en/news/278775473.md)
- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/en/news/278565253.md)
- [Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting](https://longbridge.com/en/news/278091205.md)
- [Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend](https://longbridge.com/en/news/278547270.md)